Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis by Jacob, J et al.
RESEARCH ARTICLE Open Access
Chronic hypersensitivity pneumonitis:
identification of key prognostic
determinants using automated CT analysis
Joseph Jacob1* , Brian J. Bartholmai2, Ryoko Egashira3, Anne Laure Brun1, Srinivasan Rajagopalan4, Ronald Karwoski4,
Maria Kokosi5, David M. Hansell1 and Athol U. Wells5
Abstract
Background: Chronic hypersensitivity pneumonitis (CHP) has a variable disease course. Computer analysis of CT
features was used to identify a subset of CHP patients with an outcome similar to patients with idiopathic pulmonary
fibrosis (IPF).
Methods: Consecutive patients with a multi-disciplinary team diagnosis of CHP (n = 116) had pulmonary function tests
(FEV1, FVC, DLco, Kco, and a composite physiologic index [CPI]) and CT variables predictive of mortality evaluated by
analysing visual and computer-based (CALIPER) parenchymal features: total interstitial lung disease (ILD) extent,
honeycombing, reticular pattern, ground glass opacities, pulmonary vessel volume (PVV), emphysema, and traction
bronchiectasis. Mean survival was compared between both CHP and IPF patients (n = 185).
Results: In CHP, visual/CALIPER measures of reticular pattern, honeycombing, visual traction bronchiectasis, and CALIPER
ILD extent were predictive of mortality (p < 0 · 05) on univariate analysis. PVV was strongly predictive of mortality on
univariate (p < 0 · 0001) and multivariate analysis independent of age, gender and disease severity (represented
by the CPI [p < 0 · 01]). CHP patients with a PVV threshold >6 · 5% of the lung had a mean survival (35 · 3 ± 6 · 1 months;
n = 20/116 [17%]) and rate of disease progression that closely matched IPF patients (38 · 4 ± 2 · 2 months; n = 185).
Conclusions: Pulmonary vessel volume can identify CHP patients at risk of aggressive disease and a poor IPF-like prognosis.
Keywords: Chronic hypersensitivity pneumonitis, Pulmonary vessel volume, Idiopathic pulmonary fibrosis, Quantitative
CT analysis
Background
The majority of patients with hypersensitivity pneumon-
itis who present to specialist centres have the chronic
fibrotic form of the disease [1–3]. Within the population
of chronic hypersensitivity pneumonitis (CHP) patients,
it has been observed that some patients may show an ac-
celerated rate of progression, comparable to the trajec-
tory of idiopathic pulmonary fibrosis (IPF) [2, 4, 5]. The
overlap with IPF is also evident in the often-challenging
differentiation of CHP from IPF in a multi-disciplinary
team (MDT) setting [5–7]. The early identification of a
rapidly progressive fibrosing lung disease is increasingly
relevant in an era of anti-fibrotic therapies, in which
treatment guidelines are likely to increasingly broaden
the spectrum of diagnoses for which anti-fibrotic treat-
ment is indicated.
Given the varied outcome and unpredictable prognosis
in CHP, the American National Heart, Lung and Blood
Institute, in collaboration with the Office of Rare
Diseases, convened a workshop in 2005 to discuss future
research priorities in HP [8]. Amongst the various rec-
ommendations was a need to improve the characterisa-
tion of different HP phenotypes. The workshop also
emphasized the desirability of exploring quantitative CT
analysis in longitudinal studies of HP patients [8].
Automated computer-based quantitative imaging has
advanced rapidly in recent years, with quantitatively
scored CT variables shown to be superior to visual CT
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scores in predicting mortality in IPF. [9] To date how-
ever, quantitative CT tools have not been applied to the
study of outcome in patients with CHP. Our study spe-
cifically set out to identify whether, in patients without
end-stage lung disease, there are visual or quantitative
CT features that characterize CHP patients who have a
poor IPF-like outcome.
Methods
Study population and clinical information
All new consecutive patients with an MDT diagnosis of
CHP and IPF according to published guidelines [10–12],
over a four and a half year period (January 2007–July
2011) were identified from the Interstital Lung Disease
Unit database. Patients with a non-contrast, supine,
volumetric thin-section CT were captured. Individuals
with no overt CT signs of fibrosis (the absence of honey-
combing/reticular pattern/traction bronchiectasis on vis-
ual scoring by both radiologist scorers, RE and ALB)
were excluded from analysis (Fig. 1).
Approval for this retrospective study of clinically indi-
cated CT and pulmonary function test (PFT) data was
obtained from the Institutional Ethics Committee and
informed patient consent was not required.
CT scanning, echocardiography, PFT protocols were
as previously described [9, 13] and are included in the
online appendices. CALIPER CT data processing steps
[9, 13] are also detailed in the online appendices.
CALIPER CT pattern quantitation
CALIPER evaluation of CT data involved algorithmic
identification and volumetric quantification of 15x15x15
voxel volume units into one of six radiological parenchy-
mal features: ground glass opacity (GGO), reticular pat-
tern, honeycombing, emphysema, pulmonary vessel
volume (PVV), and normal lung (Figs. 2 and 3).
A fibrosis score represented the sum of reticular
pattern and honeycombing whilst the ILD extent add-
itionally summed GGO extent. PVV represented the
sum of the volumes of the pulmonary arteries and
veins, excluding vessels at the lung hilum. All paren-
chymal pattern volumes were divided by the total
lung volume, also derived by CALIPER, to generate
percentages for each pattern.
Fig. 1 Flowchart illustrating the selection of patients for the final chronic hypersensitivity pneumonitis study population. ILD = interstitial lung
disease, CTD= connective tissue disease, CHP= chronic hypersensitivity pneumonitis, LCH= Langerhans cell histiocytosis, LAM= lymphangioleiomyomatosis,
CT = computed tomography
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CT visual quantitation
Each CHP CT was evaluated independently by two radi-
ologists (ALB, RE with 5 and 7 years thoracic imaging
experience respectively), blinded to all clinical informa-
tion. Methods by which discordant CT scores were con-
sensed are given in the Additional file 1.
Additional visually quantified CT features included
consolidation, mosaicism (decreased attenuation compo-
nent), and traction bronchiectasis (no comparable CALI-
PER score) [details in Additional file 1]. There was no
analogous visual score of PVV. A CT index of pulmon-
ary hypertension (main pulmonary artery:ascending
aorta ratio) was recorded by a single scorer using
electronic caliper measurements of the ascending
aorta and pulmonary artery diameters at the level of
the pulmonary artery bifurcation [14, 15]. A CT UIP
pattern was evaluated by one radiologist (JJ, with
5 years thoracic imaging experience) who was blinded
to all clinical information.
Identification of CHP patients with end-stage disease
The study aim was to identify characteristics of the
subset of CHP patients who do not have end-stage
disease yet progress to death rapidly with an IPF-like
trajectory. Two methods were used to identify CHP
with end stage disease:
1. Contained within the consecutive CHP cases were
individuals with respiratory failure secondary to end-
stage fibrosing lung disease, which in itself predicates
a poor outcome. Pa02 values were examined to separate
out patients who would have an inevitably rapid decline
because of end-stage disease at baseline. 102/129 (79%)
patients had a measured Pa02. Patients were identified
as having end-stage disease if they had a Pa02 < 7 · 5kPa
(n = 13). In the 27 patients without a measured Pa02,
the use of supplementary oxygen therapy (recommended
at a threshold of <7 · 3kPa02 [10]) was used to identify
patients with respiratory failure and therefore end-stage
disease (n= 3). The first study group consisted of 116
CHP patients.
2. A threshold of FVC ≥ 50% predicted was also used
to separate CHP patients into those with and without
end-stage disease at baseline. 98/123 (80%) patients had a
FVC≥ 50% predicted. In 6 patients without a measured
FVC, only one patient required supplemental home
oxygen and was therefore excluded. The second study
group consisted of 103 CHP patients. Analysis of this
second population of non end-stage CHP patients is
provided in Additional files 1, Additional file 2 and 3.
Statistical analysis
Data are given as medians, means with standard devia-
tions, or numbers of patients with percentages where
Fig. 2 Axial CT image in a 46-year-old female never smoker (a), diagnosed with chronic hypersensitivity pneumonitis following surgical lung biopsy.
An upper lobe predominant fibrosing lung disease associated with honeycomb cysts is demonstrated. On the CALIPER colour overlay image
(b), ground glass opacities (yellow) are interspaced with reticular pattern (orange) in the lung periphery. In the anterior left upper lobe,
there are honeycomb cysts visible (brown). Light and dark green areas represent normal lung parenchyma. Axial CT image in a 55-year-old female
2-pack-year ex-smoker (c), diagnosed with chronic hypersensitivity pneumonitis following surgical lung biopsy with more extensive fibrosis involving
the lower lobes. CALIPER colour overlay images show minor misclassification of traction bronchiectasis as honeycomb cysts in the left lower lobe (d),
but extensive ground glass opacities (yellow) and interspaced reticular pattern (orange)
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appropriate. Interobserver variation for visual scores
was assessed using the single determination standard
deviation. Univariate and multivariate Cox regression
analyses of the CHP cohort were used to investigate
relationships within and between the three data sets:
CALIPER CT evaluation, visual CT evaluation and
PFTs. To evaluate group differences, the T-test and
Mann Whitney U test were used for mean and me-
dian continuous variables and the Chi-squared tests
was used for categorical variables.
Cox regression analyses of CALIPER and PFT variables
were used to compare the CHP and IPF cohorts. The ro-
bustness of the results was confirmed using bootstrap-
ping and resampling of the dataset up to 1000 times.
Survival curves were created using Kaplan Meier ana-
lyses and statistically significant differences between
curves evaluated using the Log-Rank test. In all study
analyses, a p-value of <0.05 was considered significant.
Assumptions of linearity and proportional hazards were
tested by visual inspection of Martingale residuals and
scaled Schoenfeld residuals. Statistical analyses were per-
formed with STATA (version 12, StatCorp, College
Station, TX, USA).
Results
Demographic data
The initial study population, which has not been previously
described, comprised 129 consecutive patients newly pre-
senting with an MDT diagnosis of CHP based on a com-
patible clinical history and review of the following data:
antigen exposure history (positive in 53/129 [41%] patients),
precipitating antibodies (positive in 50/129 [39%] patients),
bronchoalveolar lavage (BAL) findings (performed in 73/
129 [57%] patients), CT imaging (129/129 [100%] of pa-
tients), and histopathology (60/129 [46%] of patients).
The median age at presentation was 60 years. Patient
status and mean follow up time (58.0 ± 17 · 5 months)
were obtained by contacting the patient’s primary care
giver on a given date. 50/129 patients (39%) died during
the study period. Data on vital status was completed on
98% of cases with 3 patients censored. 41/73 (56%) pa-
tients undergoing BAL had a lymphocytosis ≥20% and
25/73 (34%) had a lymphocytosis ≥30%. A right ven-
tricular systolic pressure (RVSP) >50 mmHg measured
on transthoracic echocardiography was considered rep-
resentative of pulmonary hypertension [16], and was
found in 10/69 (14%) of the CHP cohort.
Fig. 3 Corresponding axial CT images and colour overlay maps of CALIPER quantitation of pulmonary vessel volume (red), a volumetric measure
of pulmonary arteries and veins within the lung, excluding vessels at the lung hilum in three chronic hypersensitivity pneumonitis patients with
mild (a + b), moderate (c + d) and severe (e + f) extents of fibrosis. Note there is misclassification of small regions of the reticular pattern in the
paravertebral regions (b) and right lower lobe (f) as vessels
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When separating the CHP population into those with
and without end-stage disease using a PaO2 threshold of
7 · 5kPa02, using Kaplan Meier curves, the 7 · 5kPa02
threshold was shown to clearly distinguish groups with a
good and bad outcome (Log rank p < 0.0001) (Fig. 4).
The primary study group consisted of 116 CHP patients.
Demographic data and average visual score, CALIPER
score and PFT data are provided in Table 1. Interob-
server variation values for the visual scores are provided
in Additional file 1 (Table 1).
CHP mortality analyses
Strong univariate CALIPER and visually-scored CT pre-
dictors of mortality in the CHP cohort included reticular
pattern, honeycombing, visual traction bronchiectasis,
PVV and the fibrosis score (Table 2). CALIPER and visu-
ally scored emphysema were not predictive of survival.
On bivariate analyses, PVV was a stronger predictor of
mortality than FVC, DLco, and CPI (Additional file 1
[Table 2]). The results were maintained following adjust-
ment for patient age and gender with no PFTs retaining
significance in the model. In a subanalysis of CHP pa-
tients with either histopathological confirmation or anti-
body positivity to precipitating antigens, after adjusting
for patient age and gender, PVV (p = 0 · 005) remained a
stronger predictor of mortality than FVC (p = 0 · 10),
DLco (p = 0 · 009) and CPI (p = 0 · 01).
Benchmarking of an IPF outcome in patients with CHP
A consecutive population of IPF patients (n = 283), pre-
senting to our institution over the same period as the
CHP study population was analyzed to establish a mor-
tality profile of IPF. The IPF population has been previ-
ously evaluated in two studies [9, 13]. To identify and
exclude patients with respiratory failure and end-stage
disease, in a similar way to the CHP cohort, all IPF pa-
tients without a measured Pa02 (n = 70), as well as those
patients with a Pa02 < 7 · 5kPa (n = 28) were excluded.
185 IPF patients were subsequently evaluated with
Kaplan Meier analysis which identified the mean survival
to be 38 · 4 ± 2 · 2 months (Fig. 5). Of the final population
of 185 IPF patients, 74/185 (40%) patients demonstrated
a definite UIP pattern on CT and 102/185 (55%) patients
demonstrated a possible UIP pattern on CT. 9/185 (5%)
patients had a CT pattern that was inconsistent with a
UIP pattern, but which was characterised as UIP on
open lung biopsy, and confirmed as IPF following MDT
discussion with no support for a diagnosis of CHP or
connective tissue disease related-ILD (alternative expla-
nations of UIP).
Derivation of poor-outcome using PVV thresholds
CHP patients with an IPF-like outcome were identified by
separating the CHP population into two age and gender-
matched cohorts comprising 58 patients (Additional file 1
[Table 3]). No significant differences were identified for PFTs
or CT parenchymal pattern scores between groups. Various
PVV thresholds predictive of mortality were investigated. A
PVV threshold >6 · 5% of the lung showed a mean survival
most comparable to IPF patients in both CHP groups:
Group 1 mean survival = 39 · 7 ± 7 · 8 months (n = 11; 19%);
Group 2 mean survival = 28 · 2 ± 8 · 1 months (n = 9; 16%).
Fig. 4 Survival curves demonstrating differences in survival between chronic hypersensitivity pneumonitis patients with differing PaO2 thresholds.
a Differences between patients with a PaO2 >7 · 5kPa (green)(n = 116; mean survival = 65 · 6 ± 2 · 9 months) and patients with a PaO2 < 7 · 5kPa
(blue)(n = 13; mean survival = 14 · 9 ± 2 · 7 months). Log rank test p = <0 · 0001. b Differences in survival between patients with a PaO2 > 8kPa
(green)(n = 112; mean survival = 66 · 0 ± 2 · 9 months) and patients with a PaO2 < 8kPa (blue)(n = 17; mean survival = 27 · 4 ± 7 · 6 months). Log
rank test p = <0 · 0001
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The two CHP groups were combined and PVV thresh-
olds were reanalyzed and compared to outcomes in the
IPF population (Fig. 5). No statistically significant differ-
ence between Kaplan Meier survival curves was identi-
fied on comparison of the IPF and poor-outcome CHP
groups when using a PVV threshold of 6 · 5% (Log rank
test p = 0 · 89).
Percent-predicted DLco and CPI thresholds indicative
of an IPF-equivalent outcome were examined in the
CHP population (n = 116) and compared to the 6 · 5%
PVV threshold. A DLco of <25% predicted was associ-
ated with a mean survival of 41 · 8 ± 8 · 1 months and a
CPI threshold >65 was associated with a mean survival
of 38 · 1 ± 6 · 1 months. The PVV threshold was a stron-
ger predictor of mortality than either PFT threshold.
Combined analysis of IPF and poor-outcome CHP cases
The 20 CHP cases with an IPF-like outcome were com-
bined with the 185 IPF cases and evaluated together
using Cox proportional hazards analyses. An MDT diag-
nosis of CHP was not associated with an improved out-
come over patients diagnosed with IPF on univariate
analysis. Results were confirmed following correction for
age, gender and disease severity (as estimated by the
CPI) and bootstrapping of 1000 samples at a confidence
interval level of 95%. Results did not change when the
70 IPF patients without a measured Pa02.were included
in the IPF cohort.
When patients were categorized as non end-stage
disease using an FVC ≥ 50% predicted threshold the
results were essentially unchanged (see Additional files 1,
Additional file 2 and 3).
Subanalysis of the poor outcome CHP population
No difference in patient age, gender or smoking history
was identified between good and bad outcome CHP pa-
tients. 13/20 (65%) of poor outcome CHP patients had
histopathological or antibody-positive confirmation of a
CHP diagnosis and more ILD measured visually (p = 0 ·
008) and by CALIPER (p < 0 · 0001) than good outcome
patients (Table 3). Overall, CALIPER variables were bet-
ter able to identify differences between CHP outcome
groups than visual CT scores. The mean FVC, DLco and
CPI between groups were significantly different (p < 0 ·
0001). However no difference was identified in either the
mean RVSP (p = 0 · 96), or an RVSP value indicative of
pulmonary hypertension [>50 mm Hg] [16] between
outcome groups. The lack of a vasculopathic signal was
reinforced by the lack of an appreciable difference in
Kco values between groups (p = 0 · 88).
Discussion
Our study is the first to our knowledge to evaluate the
prognostic value of quantitatively derived CT variables in
Table 1 Patient age, gender and mean and standard deviations
of pulmonary function indices, CALIPER and visually scored CT
parameters, and echocardiography data in patients with chronic
hypersensitivity pneumonitis. Data represent mean values with
standard deviations. CT computed tomography, FEV1 forced
expiratory volume in one second, FVC forced vital capacity,
DLco diffusing capacity for carbon monoxide, Kco carbon
monoxide transfer coefficient, TLC total lung capacity, CPI
composite physiological index, ILD interstitial lung disease,
RVSP right ventricular systolic pressure, TxBx = traction bronchiectasis.
Baseline variables in patients with hypersensitivity pneumonitis
Variable (n = 116 unless stated)
Units are percentage unless stated
Value
Median Age (years) 58 · 5
Male/female 39/77
Survival (alive/dead) 77/39
Never smokers/ever/current-smokers (n = 128) 71/42/2
Pack years 17.5 ± 16.2
Follow up time (months) 58.0 ± 17 · 5
FEV1 % predicted (n = 112) 68 · 6 ± 19 · 7
FVC % predicted (n = 112) 72 · 2 ± 22 · 8
DLco % predicted (n = 109) 42 · 9 ± 15 · 8
Kco % predicted (n = 109) 70 · 1 ± 16 · 3
TLC% predicted (n = 103) 72 · 0 ± 16 · 8
CPI (n = 108) 47 · 9 ± 15 · 2
Echocardiography RVSP (mmHg) (n = 58) 35 · 0 ± 14 · 9
CALIPER ILD extent 24 · 3 ± 22 · 5
CALIPER Fibrosis extent 4 · 8 ± 4 · 1
CALIPER Ground glass opacity 19 · 6 ± 20 · 9
CALIPER Reticular pattern 4 · 4 ± 3 · 9
CALIPER Honeycombing 0 · 3 ± 0 · 6
CALIPER Emphysema 0 · 5 ± 1 · 7
CALIPER Pulmonary vessel volume 4 · 5 ± 1 · 9
CALIPER Normal lung 70 · 7 ± 23 · 8
Visual ILD extent 62 · 1 ± 24 · 6
Visual fibrosis extent 27 · 4 ± 19 · 0
Visual Ground glass opacity 33 · 4 ± 24 · 0
Visual Reticular pattern 26 · 4 ± 18 · 2
Visual Honeycombing 0 · 9 ± 4 · 1
Visual Consolidation 0 · 8 ± 3 · 3
Visual Mosaicism 5.0 ± 7 · 1
Visual Emphysema 3 · 0 ± 8v4
Visual TxBx severity (max score 18) 5 · 9 ± 4 · 7
Main pulmonary artery diameter (mm) 29 · 6 ± 4 · 9
Ascending aorta diameter (mm) 33 · 1 ± 3 · 9
Pulmonary artery:ascending aorta ratio 0.9 ± 0 · 1
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patients with chronic hypersensitivity pneumonitis. Import-
antly, we have shown that the pulmonary vessel volume
(PVV) provides a robust prognostic signal, independent of
PFTs and thresholding of the PVV allowed clear prognostic
distinctions to be made in CHP patients. 17% of the CHP
study population had a PVV above 6 · 5% of the total lung
volume, and these patients demonstrated a rate of disease
progression, nearly identical to that of IPF.
Previous studies have reported that a proportion of
CHP patients exhibit rapid decline and progression to
Table 2 Univariate Cox regression analysis of chronic hypersensitivity pneumonitis patients demonstrating mortality according to
CALIPER indices (top white), visually derived CT indices (light grey), pulmonary function tests (dark grey), echocardiography, and
clinical indices (lower white). ILD = Interstitial lung disease, DA = decreased attenuation, TxBx = traction bronchiectasis, PA = pulmonary
artery, Ao = Aorta, PVV = pulmonary vessel volume, FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, TLC = total
lung capacity, DLco = diffusing capacity for carbon monoxide, Kco = Carbon monoxide transfer coefficient, CPI = composite physiologic
index, RVSP = right ventricular systolic pressure, NS = not significant
Number of patients Hazard ratio P value 95.0% Confidence interval
Lower Upper
Caliper indices
Total ILD extent 116 1 · 02 0 · 001 1 · 01 1 · 03
Total fibrosis extent 116 1 · 32 <0 · 0001 1 · 22 1 · 43
Ground glass opacity 116 1 · 02 0 · 02 1 · 00 1 · 03
Reticular pattern 116 1 · 33 <0 · 0001 1 · 22 1 · 44
Honeycombing 116 2 · 71 0 · 001 1 · 54 4 · 76
Emphysema 116 NS
Normal lung 116 0 · 98 0 · 001 0 · 97 0 · 99
PVV 116 1 · 56 <0 · 0001 1 · 31 1 · 84
Visual indices
ILD extent 116 NS
Fibrosis extent 116 1 · 06 <0 · 0001 1 · 04 1 · 08
Ground glass opacity 116 0 · 98 0 · 02 0 · 97 1 · 00
Reticular pattern 116 1 · 05 <0 · 0001 1 · 03 1 · 07
Honeycombing 116 1 · 19 0 · 001 1 · 07 1 · 31
Consolidation 116 NS
Total emphysema 116 NS
Mosaicism 116 NS
TxBx severity 116 1 · 16 <0 · 0001 1 · 09 1 · 23
Main PA 116 1 · 09 0 · 002 1 · 03 1 · 15
Aorta 116 NS
PA:Ao ratio 116 1 · 03 0 · 02 1 · 01 1 · 05
Pulmonary function indices
FEV1 112 0 · 98 0 · 02 0 · 96 1 · 00
FVC 112 0 · 98 0 · 006 0 · 97 0 · 99
TLC 103 0 · 96 0 · 0001 0 · 93 0 · 98
DLco 109 0 · 96 0 · 001 0 · 93 0 · 98
Kco 109 NS
CPI 108 1 · 04 0 · 001 1 · 02 1 · 07
Other indices
ECHOCARDIOGRAPHY RVSP 58 NS
Age 116 NS
Gender 116 NS
Smoking history 115 NS
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death, similar to patients with IPF [4, 5]. A study of 47
histologically-confirmed UIP patients performed by
Pérez-Padilla et al [4] showed that after correcting for
CT disease extent, patients exposed to avian antigens
had similar outcomes to patients unexposed to avian an-
tigens [4]. A study by Mooney et al [17] demonstrated
that the quartile of CHP patients with the most exten-
sive fibrosis (the sum of visual CT reticulation and
honeycomb extent scores), had an outcome comparable
to IPF at 4 years. However the study by Mooney et al in-
cluded CHP patients with respiratory failure and end-
stage disease who would be expected to have a poor,
IPF-like outcome. In our study our specific aim was to
demonstrate that even with the exclusion of patients
with end-stage disease, a proportion of CHP patients
progress to death with an IPF-like disease course.
A prior study in CHP patients with interspaced CT
imaging demonstrated that computer-derived CT vari-
ables were strongly predictive of mortality [18]. However
the interspaced nature of the dataset precluded certain
variables such as the pulmonary vessel volume form be-
ing adequately examined as a predictor of mortality.
Given that a previous report in patients with IPF dem-
onstrated the PVV to be the strongest CT variable for
predicting mortality [9], it was a logical step to examine
this key variable in a separate CHP population with
volumetric CT imaging. The similar severity-adjusted
survival between a subgroup of CHP patients and IPF
Fig. 5 Survival curves for patients with idiopathic pulmonary fibrosis (IPF) (yellow) and chronic hypersensitivity pneumonitis (CHP) (green and blue). CHP
cases with end stage disease (denoted by a PaO2 < 7 · 5kPa) were excluded. IPF cases without a measured PaO2 or with end stage disease (denoted by a
PaO2 < 7 · 5kPa) were excluded. IPF patients (n= 185) were compared to CHP cases at pulmonary vessel volume (PVV) thresholds above (green) and below
(blue) 5%, 5 · 5%, 6 · 5% and 7% (a–d). The IPF and poor-outcome CHP curves were most comparable at a CHP PVV threshold of 6 · 5% where the mean
survival in the IPF population (38 · 4 ± 2 · 2 months; n = 185) was found to be similar to the poor-outcome CHP population (35 · 3 ± 6 · 1 months; n = 20)
and distinct from the good-outcome CHP population (71 · 3 ± 2 · 8 months; n = 96). The PVV > 6% threshold contained only two patients more than the
PVV > 6 · 5% threshold which did not significantly alter the results and accordingly was not been formally plotted
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patients identified in the current study corroborates pre-
vious observations that a subset of CHP patients have an
outcome nearly identical to IPF. [2, 4, 5] Whilst our
findings do not identify the mechanism for this differ-
ence, three potential contributing factors could be
considered.
Firstly, the PVV threshold may identify CHP patients
that have more aggressive lung disease. Alternatively
PVV may be providing added information regarding pul-
monary vasculopathy, though the similarities in RVSP
and Kco between good and bad outcome CHP groups
makes this unlikely. Lastly vessel size may be a better
marker of interstitial severity than functional indices.
The high negative intrathoracic pressures generated dur-
ing respiration in patients with fibrosing lung disease
may increase as fibrosis worsens, drawing extra blood
into the lungs as well as concomitantly exerting a pull
on pulmonary vessel walls. The mortality signal associ-
ated with a high PVV may therefore reflect worsening
pulmonary fibrosis.
Intriguingly, a study evaluating pulmonary angiogen-
esis in patients with CHP has identified elevated levels
Table 3 Patient demographics, pulmonary function indices, CALIPER and visually scored CT parameters and echocardiography data
in 2 groups of chronic hypersensitivity pneumonitis patients. Group 1 had an IPF-like outcome (n = 20) and group 2 had a good
outcome (n = 96). Differences between groups were assessed using the T-test for continuous variables, the Mann Whitney U test for
differences in continuous median values and the Chi-Squared test for categorical variables. CT = computed tomography, FEV1 =
forced expiratory volume in one second, FVC = forced vital capacity, DLco = diffusing capacity for carbon monoxide, Kco = carbon monoxide
transfer coefficient, TLC = total lung capacity, CPI = composite physiological index, ILD = interstitial lung disease, RVSP = right ventricular
systolic pressure TxBx = traction bronchiectasis, PA = pulmonary artery. Comparison of hypersensitivity pneumonitis patients groups: IPF-like
versus non-IPF-like outcome
Variable
Units are percentage unless stated
Group 1
(n = 20 unless stated
in brackets)
Group 2
(n = 96 unless stated
in brackets)
Group Differences
Median Age (years) 56 · 5 59 NS
Male/female 7/13 32/64 NS
Survival (alive/dead) 6/14 71/25 <0 · 0001
Never/ever/current smokers 15/4/0 (19) 56/38/2 NS
Pack years 28 · 5 ± 26 · 5 16 · 4 ± 14 · 9 NS
FEV1 % predicted 48 · 1 ± 12 · 1 (18) 72 · 5 ± 18 · 4 (94) <0 · 0001
FVC % predicted 45 · 6 ± 10 · 8 (18) 77 · 3 ± 20 · 9 (94) <0 · 0001
DLco % predicted 28 · 1 ± 8 · 4 (16) 45 · 5 ± 15 · 4 (93) <0 · 0001
Kco % predicted 70 · 4 ± 16 · 4 (16) 70 · 1 ± 16 · 3 (93) NS
TLC% predicted 50 · 9 ± 7 · 2 (14) 75 · 3 ± 15 · 4 (89) <0 · 0001
CPI 64 · 6 ± 6 · 5 (16) 45 · 0 ± 14 · 3 (92) <0 · 0001
Echocardiography RVSP (mmHg) 33 · 0 ± 6 · 5 (8) 35 · 4 ± 15 · 9 (50) NS
CALIPER ILD extent 58 · 6 ± 17 · 2 17 · 2 ± 15 · 9 <0 · 0001
CALIPER Ground glass opacity 48 · 7 ± 21 · 1 13 · 5 ± 14 · 9 <0 · 0001
CALIPER Reticular pattern 9 · 4 ± 5 · 1 3 · 4 ± 2 · 5 <0 · 0001
CALIPER Honeycombing 0 · 5 ± 1 · 1 0 · 3 ± 0 · 4 NS
CALIPER Emphysema 0 · 2 ± 0 · 4 0 · 5 ± 1 · 8 NS
CALIPER Pulmonary vessel volume 7 · 7 ± 0v8 3 · 8 ± 1 · 3 <0 · 0001
Visual ILD extent 74 · 9 ± 17 · 4 59 · 5 ± 25 · 1 =0 · 002
Visual Ground glass opacity 24 · 1 ± 13 · 5 35 · 3 ± 25 · 3 =0.006
Visual Reticular pattern 44 · 4 ± 14 · 7 22 · 7 ± 16 · 6 <0 · 0001
Visual Honeycombing 3 · 6 ± 9 · 5 0 · 4 ± 1 · 1 NS
Visual Emphysema 0 · 3 ± 0 · 5 3 · 5 ± 9 · 2 =0 · 001
Visual TxBx severity (max score 18) 9 · 2 ± 4 · 9 5 · 2 ± 4 · 4 =0 · 0004
Main PA diameter (mm) 31 · 5 ± 4 · 5 29 · 2 ± 4 · 9 NS
Ascending aorta diameter (mm) 32 · 2 ± 4 · 3 33 · 3 ± 3 · 9 NS
PA:ascending aorta ratio 1.0 ± 0.2 0.9 ± 0.1 =0.006
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of vascular endothelial growth factor in the lungs of
CHP patients when compared to control subjects [19].
Angiogenesis represents a physiological, hypoxia-
induced response within the tissues to facilitate improve-
ments in gas exchange. Therefore an increase in the
PVV may represent a response to the progressive im-
pairment in gas exchange that results as the interstitial
damage progresses.
The PVV threshold of >6 · 5% of the lung demon-
strated a stronger distinction between groups than any
individual PFT and has the additional benefit of avoiding
the issue of observer disagreement associated with sub-
jective visual CT scoring. Furthermore, given recent evi-
dence suggesting variability between MDTs in making a
CHP diagnosis [7], we were able to confirm the PVV sig-
nal strength in patients with either a histopathological
CHP diagnosis or antibody positivity.
Significant univariate predictors of mortality in the
current study are in line with previous reports that have
identified CT markers of fibrosis including reticulation
[17], honeycombing [20, 21], traction bronchiectasis [3]
and a fibrosis score (sum of reticulation and honey-
combing) [1, 17, 22] as predictors of a poor prognosis in
CHP. A mosaic attenuation pattern (scored as the de-
creased attenuation component), however, was not pre-
dictive of mortality in contrast to the findings in
histopathologically proven CHP cases of Lima et al. [1]
Emphysema extent scored on CT had no bearing on
prognosis, a result which could arguably be reconciled
with the relatively limited extent of emphysema in our
CHP cohort.
In the CHP group with an IPF-like outcome, the ma-
jority (79%) of patients were never smokers and unlike
previous reports in CHP, smoking was not associated
with a worse outcome [23]. Similarly, the presence of
pulmonary hypertension was not associated with a wors-
ened prognosis in contrast to the study by Koschel et al.
[24] However the study by Koschel et al [24] did not
correct for baseline disease extent when analyzing out-
come in CHP patients with pulmonary hypertension
which could have negated the study findings.
Of the PFTs, the total lung capacity (TLC) was the
strongest predictor of mortality on univariate analysis,
echoing the findings of Mooney et al [17]. However, the
same association of TLC with mortality was not repli-
cated in a study by Vourlekis et al [2]. On multivariate
analysis, CT variables, particularly CALIPER PVV, were
stronger predictors of mortality than FVC, DLco, and
CPI. The findings mirror the results of the study by
Walsh et al which reported the superiority of visual
CT variables over any PFTs in predicting mortality in
CHP [3].
In our analysis, we deliberately excluded patients with
end-stage fibrosing lung disease to allow the identification
of patients at risk of a poor outcome, but in whom, tar-
geted intervention might reasonably be expected to mod-
ify disease progression. Patients with end-stage disease,
characterized by the requirement of oxygen therapy at
rest, more usually enter palliative care pathways rather
than aggressive medical treatment. The poor outcome of
such end-stage CHP cases was highlighted in the study by
Mooney et al in which, unsurprisingly, oxygen therapy
was shown to be predictive of mortality on multivariate
analysis [17]. In our study, with the exclusion of end-stage
patients, a significant proportion of CHP patients (17%)
had an outcome comparable to IPF.
There are limitations to the current study. In an era in
which the MDT diagnosis is the accepted diagnostic
standard, the number of patients undergoing surgical bi-
opsy for tissue diagnosis is inevitably reduced. Though
only 46% of patients in the final study had a surgical bi-
opsy, the diagnosis of CHP on a histopathological exam-
ination alone may not be definitive, as studies have
shown that the majority of biopsy samples do not show
all of the classical pathological features [1, 6]. The PVV
variable was found to be liable to minor contamination
as areas of reticular pattern, predominantly in the lung
periphery, were captured and classified as vessels. The
noise associated with the PVV signal when improved in
future iterations of similar software would likely
strengthen our observations. Though the median age of
our CHP population was slightly higher than several
prior CHP studies [2, 25, 26], it was similar to the study
by Mooney et al [17] whilst the median age of the poor-
outcome CHP group was similar to the HP population
in the study by Lacasse et al [25]. We do not believe that
these limitations diminish the applicability of our results
to patients with an MDT diagnosis of CHP.
Conclusions
In conclusion, we have demonstrated that a significant
proportion of CHP patients have an IPF-like outcome
and that this can be predicted from the PVV derived
from CALIPER software. This novel finding may have a
role in identifying the subgroup of CHP patients who
may benefit from close monitoring and intervention to
control disease progression.
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